Literature DB >> 32963375

The search for Alzheimer disease therapeutics - same targets, better trials?

Michael S Rafii1, Paul S Aisen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32963375     DOI： 10.1038/s41582-020-00414-3

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

Review 1.  BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease.

Authors:  Nour M Moussa-Pacha; Shifaa M Abdin; Hany A Omar; Hasan Alniss; Taleb H Al-Tel
Journal:  Med Res Rev       Date:  2019-07-26       Impact factor: 12.944

2.  Lowering of Amyloid-Beta by β-Secretase Inhibitors - Some Informative Failures.

Authors:  David S Knopman
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

3.  A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Authors:  Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

Review 4.  TREM2 - a key player in microglial biology and Alzheimer disease.

Authors:  Tyler K Ulland; Marco Colonna
Journal:  Nat Rev Neurol       Date:  2018-11       Impact factor: 42.937

5.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.

Authors:  Michael C Donohue; Reisa A Sperling; Ronald Petersen; Chung-Kai Sun; Michael W Weiner; Paul S Aisen
Journal:  JAMA       Date:  2017-06-13       Impact factor: 56.272

6.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Authors:  Stephen Salloway; Reisa Sperling; Nick C Fox; Kaj Blennow; William Klunk; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Steven Ferris; Marcel Reichert; Nzeera Ketter; Bijan Nejadnik; Volkmar Guenzler; Maja Miloslavsky; Daniel Wang; Yuan Lu; Julia Lull; Iulia Cristina Tudor; Enchi Liu; Michael Grundman; Eric Yuen; Ronald Black; H Robert Brashear
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

7.  Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

Authors:  Jeffrey L Cummings; Travis Morstorf; Kate Zhong
Journal:  Alzheimers Res Ther       Date:  2014-07-03       Impact factor: 6.982

8.  Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report.

Authors:  Joseph F Arboleda-Velasquez; Francisco Lopera; Michael O'Hare; Santiago Delgado-Tirado; Claudia Marino; Natalia Chmielewska; Kahira L Saez-Torres; Dhanesh Amarnani; Aaron P Schultz; Reisa A Sperling; David Leyton-Cifuentes; Kewei Chen; Ana Baena; David Aguillon; Silvia Rios-Romenets; Margarita Giraldo; Edmarie Guzmán-Vélez; Daniel J Norton; Enmanuelle Pardilla-Delgado; Arabiye Artola; Justin S Sanchez; Juliana Acosta-Uribe; Matthew Lalli; Kenneth S Kosik; Matthew J Huentelman; Henrik Zetterberg; Kaj Blennow; Rebecca A Reiman; Ji Luo; Yinghua Chen; Pradeep Thiyyagura; Yi Su; Gyungah R Jun; Marcus Naymik; Xiaowu Gai; Moiz Bootwalla; Jianling Ji; Lishuang Shen; John B Miller; Leo A Kim; Pierre N Tariot; Keith A Johnson; Eric M Reiman; Yakeel T Quiroz
Journal:  Nat Med       Date:  2019-11-04       Impact factor: 53.440

Review 9.  The amyloid hypothesis of Alzheimer's disease at 25 years.

Authors:  Dennis J Selkoe; John Hardy
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

10.  Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.

Authors:  Gregory Klein; Paul Delmar; Nicola Voyle; Sunita Rehal; Carsten Hofmann; Danielle Abi-Saab; Mirjana Andjelkovic; Smiljana Ristic; Guoqiao Wang; Randall Bateman; Geoffrey A Kerchner; Monika Baudler; Paulo Fontoura; Rachelle Doody
Journal:  Alzheimers Res Ther       Date:  2019-12-12       Impact factor: 6.982
  10 in total
  6 in total

Review 1.  Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise.

Authors:  Fei Yin
Journal:  FEBS J       Date:  2022-01-07       Impact factor: 5.622

Review 2.  A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials.

Authors:  Mitzi M Gonzales; Sudarshan Krishnamurthy; Valentina Garbarino; Ali S Daeihagh; Gregory J Gillispie; Gagan Deep; Suzanne Craft; Miranda E Orr
Journal:  Mech Ageing Dev       Date:  2021-10-21       Impact factor: 5.498

3.  Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.

Authors:  P S Aisen; R J Bateman; M Carrillo; R Doody; K Johnson; J R Sims; R Sperling; B Vellas
Journal:  J Prev Alzheimers Dis       Date:  2021

4.  Self-reference Network-Related Interactions During the Process of Cognitive Impairment in the Early Stages of Alzheimer's Disease.

Authors:  Ping-Hsuan Wei; Haifeng Chen; Qing Ye; Hui Zhao; Yun Xu; Feng Bai
Journal:  Front Aging Neurosci       Date:  2021-03-24       Impact factor: 5.750

5.  Neurotrophic factor-secreting cells restored endogenous hippocampal neurogenesis through the Wnt/β-catenin signaling pathway in AD model mice.

Authors:  Gozal Bahlakeh; Reza Rahbarghazi; Ali Abedelahi; Saeed Sadigh-Eteghad; Mohammad Karimipour
Journal:  Stem Cell Res Ther       Date:  2022-07-26       Impact factor: 8.079

6.  Neurology at the crossroads.

Authors: 
Journal:  Nat Rev Neurol       Date:  2020-11       Impact factor: 42.937
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.